NewAmsterdam Pharma Warrant (NAMSW)

• Market cap: $100M
• 1 day: -2.16%
• 5 days: -21.01%
• 1 month: -27.34%
• 3 months: 42.75%
• 6 months: 122.82%
• Year to date: 51.29%
• 1 year: 46.6%
• 5 years: 2,373.86%
• 10 years: 2,373.86%
• Sector: Healthcare
• Industry: Biotechnology

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Employees: 77